Quick New Member Take: 3 Questions to Strike Pharma

We warmly welcome Strike Pharma as a new member of our life science park, located at Smile Venture Hub. We asked their CEO Per Norlén to answer three key questions and share insights into how they aim to make a difference in our community and the industry in our region:

How can the life science community in southern Sweden benefit from your membership at Medicon Village?

We have recently established our presence in Lund at Medicon Village by joining the SmiLe Venture Hub and plan to relocate all activities here from Uppsala. Strike Pharma is developing a technology platform for targeted nanoparticle delivery, building on expertise in nanoparticles, nucleotide/gene therapy, and the development of monoclonal antibodies. Being at the crossroads of different disciplines, we have the potential to collaborate with many different companies and academic groups.

What is your perspective on the opportunities for the Swedish life science industry to strengthen its international relations?

Our technology enables the generation of in vivo CAR-T therapies, which is one of the most progressive fields within drug development internationally. We thus expect to contribute to the strengthening of international collaborations through multiple partnerships.

What are your major challenges in the coming year to meet market demands and trends?

We are at the forefront of exploring ways to reprogramme T cells using targeted LNP delivery, i.e., without the use of viral vectors. The key challenges ahead are to demonstrate that our technology enables effective reprogramming while reducing costs and risks. The uncertain financial market is, of course, challenging for drug development companies, given that the timelines are usually relatively long. Fortunately, we have strong specialist investors supporting our journey ahead.

More information on Strike Pharma at https://www.mediconvillage.se/member/strike-pharma.